CompletedNCT00485459
Atomoxetine for ADHD in children and teens in Taiwan
About this title
Read the official source — NCT00485459This study evaluated the safety and effectiveness of Atomoxetine Hydrochloride for people with ADHD.
Medication studyAges 6–16Taiwan
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Atomoxetine Hydrochloride for people with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 16 years. Other eligibility criteria applied.
- Listed locations
- TaipeiSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateFebruary 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 106
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Taiwan
- Age range
- From 6 Years to 16 Years
- Official registry ID
- NCT00485459
- Official title
Show the full official title
Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Taipei
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Atomoxetine Hydrochloride for people with ADHD.
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine Hydrochloride and Placebo.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 16 years. Other eligibility criteria applied.
